Logo image of ARBS.MI

ARTERRA BIOSCIENCE SPA (ARBS.MI) Stock Fundamental Analysis

BIT:ARBS - Euronext Milan - IT0005386369 - Common Stock - Currency: EUR

2.28  +0.04 (+1.79%)

Fundamental Rating

4

Overall ARBS gets a fundamental rating of 4 out of 10. We evaluated ARBS against 0 industry peers in the Unkown industry. The financial health of ARBS is average, but there are quite some concerns on its profitability. ARBS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ARBS was profitable.
ARBS had a positive operating cash flow in the past year.
In the past 5 years ARBS has always been profitable.
ARBS had a positive operating cash flow in each of the past 5 years.
ARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFARBS.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M

1.2 Ratios

Industry RankSector Rank
ROA 9.97%
ROE 11.7%
ROIC 8.8%
ROA(3y)9.93%
ROA(5y)10.02%
ROE(3y)11.74%
ROE(5y)12.1%
ROIC(3y)9.13%
ROIC(5y)9.66%
ARBS.MI Yearly ROA, ROE, ROICARBS.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

In the last couple of years the Profit Margin of ARBS has remained more or less at the same level.
ARBS's Operating Margin has been stable in the last couple of years.
In the last couple of years the Gross Margin of ARBS has remained more or less at the same level.
Industry RankSector Rank
OM 32.91%
PM (TTM) 32.04%
GM 57.85%
OM growth 3Y0.28%
OM growth 5Y-1.05%
PM growth 3Y3.33%
PM growth 5Y0.25%
GM growth 3Y-2.51%
GM growth 5Y-0.98%
ARBS.MI Yearly Profit, Operating, Gross MarginsARBS.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARBS is destroying value.
ARBS has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARBS has less shares outstanding
ARBS has a better debt/assets ratio than last year.
ARBS.MI Yearly Shares OutstandingARBS.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ARBS.MI Yearly Total Debt VS Total AssetsARBS.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 6.69 indicates that ARBS is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of ARBS is 0.89, which is an excellent value as it means it would take ARBS, only 0.89 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.02 indicates that ARBS is not too dependend on debt financing.
Even though the debt/equity ratio score it not favorable for ARBS, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.89
Altman-Z 6.69
ROIC/WACC0.91
WACC9.68%
ARBS.MI Yearly LT Debt VS Equity VS FCFARBS.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.3 Liquidity

ARBS has a Current Ratio of 10.20. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
ARBS has a Quick Ratio of 8.58. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 10.2
Quick Ratio 8.58
ARBS.MI Yearly Current Assets VS Current LiabilitesARBS.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.90% over the past year.
ARBS shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.01% yearly.
ARBS shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.29%.
Measured over the past years, ARBS shows a quite strong growth in Revenue. The Revenue has been growing by 9.02% on average per year.
EPS 1Y (TTM)20.9%
EPS 3Y8.02%
EPS 5Y10.01%
EPS Q2Q%-5.62%
Revenue 1Y (TTM)26.29%
Revenue growth 3Y2.94%
Revenue growth 5Y9.02%
Sales Q2Q%12.32%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARBS.MI Yearly Revenue VS EstimatesARBS.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 10.86, the valuation of ARBS can be described as very reasonable.
The average S&P500 Price/Earnings ratio is at 26.29. ARBS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.86
Fwd PE N/A
ARBS.MI Price Earnings VS Forward Price EarningsARBS.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 38.02
EV/EBITDA 7.12
ARBS.MI Per share dataARBS.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.08
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.70%, ARBS is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.38, ARBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.7%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

49.81% of the earnings are spent on dividend by ARBS. This is a bit on the high side, but may be sustainable.
DP49.81%
EPS Next 2YN/A
EPS Next 3YN/A
ARBS.MI Yearly Income VS Free CF VS DividendARBS.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
ARBS.MI Dividend Payout.ARBS.MI Dividend Payout, showing the Payout Ratio.ARBS.MI Dividend Payout.PayoutRetained Earnings

More info and screens

ARTERRA BIOSCIENCE SPA

BIT:ARBS (5/20/2025, 7:00:00 PM)

2.28

+0.04 (+1.79%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner ChangeN/A
Ins Owners44.27%
Ins Owner ChangeN/A
Market Cap15.18M
Analysts82.86
Price Target3.67 (60.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.7%
Yearly Dividend0.11
Dividend Growth(5Y)N/A
DP49.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10.86
Fwd PE N/A
P/S 3.64
P/FCF 38.02
P/OCF 14.27
P/B 1.33
P/tB 1.33
EV/EBITDA 7.12
EPS(TTM)0.21
EY9.21%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.06
FCFY2.63%
OCF(TTM)0.16
OCFY7.01%
SpS0.63
BVpS1.72
TBVpS1.71
PEG (NY)N/A
PEG (5Y)1.08
Profitability
Industry RankSector Rank
ROA 9.97%
ROE 11.7%
ROCE 10.92%
ROIC 8.8%
ROICexc 11.99%
ROICexgc 12.03%
OM 32.91%
PM (TTM) 32.04%
GM 57.85%
FCFM 9.57%
ROA(3y)9.93%
ROA(5y)10.02%
ROE(3y)11.74%
ROE(5y)12.1%
ROIC(3y)9.13%
ROIC(5y)9.66%
ROICexc(3y)15.47%
ROICexc(5y)17.58%
ROICexgc(3y)15.82%
ROICexgc(5y)18.81%
ROCE(3y)11.33%
ROCE(5y)12.02%
ROICexcg growth 3Y-16.84%
ROICexcg growth 5Y-17%
ROICexc growth 3Y-14.48%
ROICexc growth 5Y-12.8%
OM growth 3Y0.28%
OM growth 5Y-1.05%
PM growth 3Y3.33%
PM growth 5Y0.25%
GM growth 3Y-2.51%
GM growth 5Y-0.98%
F-Score7
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.89
Debt/EBITDA 0.15
Cap/Depr 195.9%
Cap/Sales 15.93%
Interest Coverage 250
Cash Conversion 62.14%
Profit Quality 29.88%
Current Ratio 10.2
Quick Ratio 8.58
Altman-Z 6.69
F-Score7
WACC9.68%
ROIC/WACC0.91
Cap/Depr(3y)76.68%
Cap/Depr(5y)90.12%
Cap/Sales(3y)7.07%
Cap/Sales(5y)10.14%
Profit Quality(3y)69.73%
Profit Quality(5y)57.78%
High Growth Momentum
Growth
EPS 1Y (TTM)20.9%
EPS 3Y8.02%
EPS 5Y10.01%
EPS Q2Q%-5.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.29%
Revenue growth 3Y2.94%
Revenue growth 5Y9.02%
Sales Q2Q%12.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.64%
EBIT growth 3Y3.23%
EBIT growth 5Y7.88%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-57.65%
FCF growth 3Y-20.26%
FCF growth 5Y25.42%
OCF growth 1Y3.72%
OCF growth 3Y-8.67%
OCF growth 5Y-9.31%